Kumamoto Y, Sakai S, Tamate H, Gohro T, Inoke T, Tabata S, Tanda H, Kato S, Saka T, Henmi I
Hinyokika Kiyo. 1986 Aug;32(8):1213-23.
AT-2266 is a new antibiotic of the pyridone carboxylic acid class which possesses a broad, low-MIC antibacterial spectrum. Therapeutic studies were carried out on the use of this drug in the treatment of chronic prostatitis, and at the same time a pathological analysis was performed on chronic prostatitis. The subjects were 97 chronic prostatitis patients for whom the prostate fluid had been confirmed to contain at least 30 leukocytes per 400-power magnification field. An analysis of the background factors revealed that 71% of these patients had a past history of gonorrheal or non-gonorrheal urethritis. Culture of the prostate fluid yielded gram-positive cocci (S. epidermidis in most cases) in 44.1% of the patients. E. coli was detected in 3.2% of the patients, while the remaining cases gave negative cultures. In 53.9% of the patients who had not been receiving therapy prior to inclusion in this study, the subjective symptoms consisted of urethral irritation or irritation upon urination. In the other patients, the relationship of the complaints to the disease could not be clearly established. In the patients who had been receiving therapy, the majority did not complain of subjective symptoms. AT-2266 was administered in a daily dosage of 600 mg (in 3 divided doses) for 14 days. The therapeutic efficacy was evaluated. At the end of 7 days of AT-2266 therapy, 15.5% of the previously-untreated group and 8% of the previously-treated group were "excellent" cases, and the efficacy rate was 32.8% and 36%, respectively, when the "good" cases were also included. At the end of the full 14 days of therapy, the corresponding efficacy rates were 21.7% and 17.4%, and 54.3% and 56.5%. Considerable improvement was achieved in the subjective symptoms of urethral irritation and irritation upon urination at the end of 7 days of therapy, and the improvement was even greater following the next 7 days of treatment. With regard to the complaints for which the relationship to the disease could not be clearly established, however, the improvement was not very good: there was not much difference between the results on the 7th and 14th days, and the elimination rate even after 14 days was slightly below 30%. In the previously-untreated patients, improvement in leukocyte count in the prostate fluid to 10 or fewer cells per microscopic field was achieved in 15.6% at 7 days and 21.7% at 14 days. As side effects of AT-2266, mild symptoms were observed to occur in only 1.8% of the patients.
AT - 2266是一种新型的吡啶酮羧酸类抗生素，具有广谱、低最小抑菌浓度（MIC）的抗菌谱。对该药物治疗慢性前列腺炎进行了治疗研究，同时对慢性前列腺炎进行了病理分析。研究对象为97例慢性前列腺炎患者，其前列腺液经确认在每400倍放大视野下至少含有30个白细胞。对背景因素的分析显示，这些患者中有71%有淋菌性或非淋菌性尿道炎病史。44.1%的患者前列腺液培养出革兰氏阳性球菌（大多数情况下为表皮葡萄球菌）。3.2%的患者检测到大肠杆菌，其余病例培养结果为阴性。在本研究纳入前未接受治疗的患者中，53.9%的患者主观症状为尿道刺激或排尿时刺激。在其他患者中，症状与疾病的关系无法明确确定。在接受过治疗的患者中，大多数没有主诉主观症状。AT - 2266的给药剂量为每日600mg（分3次服用），共14天。评估了治疗效果。在AT - 2266治疗7天时，未接受过治疗的组中有15.5%、接受过治疗的组中有8%为“优”病例，若将“良”病例也包括在内，有效率分别为32.8%和36%。在治疗满14天时，相应的有效率分别为21.7%和17.4%，以及54.3%和56.5%。治疗7天时，尿道刺激和排尿时刺激的主观症状有明显改善，接下来7天治疗后改善更大。然而，对于那些与疾病关系无法明确确定的症状，改善不太理想：第7天和第14天的结果差异不大，即使在14天后消除率也略低于30%。在未接受过治疗的患者中，7天时前列腺液白细胞计数改善至每高倍视野10个或更少细胞的患者占15.6%，14天时占21.7%。作为AT - 2266的副作用，仅1.8%的患者出现轻微症状。
